Cyclosporin A therapy differently affects immunological-relevant gene expression following immunization

Related Experiment Video

Updated: Sep 29, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Laurent Mascarell1, Paolo Truffa-Bachi

  • 1Unité Biologie des Populations Lymphocytaires, Department of Immunology, CNRS URA 1961, Institut Pasteur, F-75724 Paris Cedex 15, France.

Immunology Letters
|September 25, 2002
PubMed

Insights

Cyclosporin A (CSA) treatment blocks key immune gene transcription, including IL-2 and IFN-gamma, and alters T-cell surface markers. This results in activated T-cells with a distinct phenotype, impacting immune responses.

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclosporin A (CSA) is an immunosuppressive drug widely used in transplantation and autoimmune diseases.
  • Understanding CSA's precise molecular effects on immune cell gene expression is crucial for optimizing its therapeutic use.

Purpose of the Study:

  • To investigate the impact of Cyclosporin A (CSA) on the gene expression profile of activated T-cells in a transgenic mouse model.
  • To characterize the phenotypic changes in T-cells following priming in the presence of CSA.

Main Methods:

  • Utilized a transgenic mouse model with a T cell receptor specific for pigeon cytochrome c peptide 88-104.
  • Administered CSA to mice prior to immunization and analyzed gene transcription (IL-2, IFN-gamma, CXCR-5, CCR-5, CD25) and cell surface marker expression (CD69, CCR-1, CCR-4, CXCR2, CXCR-4, CD44, CD62L) via flow cytometry and gene expression analysis.

Main Results:

  • CSA treatment led to the blockade of IL-2, IFN-gamma, CXCR-5, CCR-5, and CD25 gene transcription.
  • CSA decreased CD69 expression on T-cells but did not affect CCR-1, CCR-4, CXCR2, or CXCR-4 induction.
  • CSA accelerated the expression kinetics and increased the density of CD44 and CD62L on T-cell membranes.

Conclusions:

  • Priming T-cells in the presence of CSA results in a distinct activated T-cell phenotype.
  • CSA significantly modulates immune gene expression and T-cell surface marker profiles, influencing immune cell activation and function.

More Related Videos

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...